Bristol-Myers, Pfizer Says Eliquis Late-Stage Trial Meets Main Goal 
 Mittwoch, 13.11.2013 Börsentäglich über 12.000 News von 463 internationalen Medien Erweiterte Suche Ad hoc-Mitteilungen Startseite Nachrichten Aktienkurse Fonds Anleihen Derivate Rohstoffe Devisen Watchlist Aktien » Nachrichten » PFIZER AKTIE » Bristol-Myers, Pfizer Says Eliquis Late-Stage Trial Meets Main Goal PFIZER INC 23,403 Euro +0,152 +0,65 % WKN: 852009  ISIN: US7170811035  Ticker-Symbol: PFE  Frankfurt |  12.11.13 |  18:25 Uhr Nachrichten Analysen Kurse Chart Aktie: Branche Pharma Aktienmarkt DJ Industrial S&P 100 S&P 500 1-Jahres-Chart 1-Woche-Intraday-Chart Realtime Geld Brief Zeit 23,287 23,307 12.11. 23,337 23,39 12.11. 30.06.2013 | 23:40 (131 Leser) Schrift ändern: ( 0 Bewertungen) AFX News · Mehr Nachrichten von AFX News Bristol-Myers, Pfizer Says Eliquis Late-Stage Trial Meets Main Goal NEW YORK CITY (dpa-AFX) - Bristol-Myers Squibb Co. (BMY) and Pfizer Inc. (PFE) Sunday said its anti-clotting drug Eliquis proved to be as effective as standard therapy and caused significantly less bleeding complications in in treating patients with acute venous thromboembolism. Eliquis met the main endpoint of the trial by demonstrating that it is not inferior to the current standard of care, ainitial parenteral enoxaparin treatment overlapped with warfarin therapy, in the reduction of recurrence of acute venous thromboembolism, or VTE, and related deaths. Eliquis also met the primary safety endpoint of superiority for major bleeding, with a 69 percent relative risk reduction compared to current standard of care. Eliquis, or apixaban, is an anticoagulant that was jointly developed by Bristol-Myers Squibb and Pfizer. Eliquis is approved for prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery in the EU and other countries, but the drug has not been is not approved for this indication in the U.S. 'The study results showed that apixaban, as a single-agent, has comparable efficacy with significantly fewer major bleeding events with respect to the standard of care,' said Dr. Giancarlo Agnelli, the lead investigator of the study. 'Together these studies represent exciting data in the field of VTE treatment and indicate that apixaban may offer an important potential alternative in both acute and extended anticoagulation therapy for VTE patients.' Venous thromboembolism encompasses two serious conditions: deep vein thrombosis (DVT), a blood clot in a vein, usually in the leg; and pulmonary embolism (PE), a blood clot blocking one or more vessels in the lungs. Around 900,000 patients in the U.S. and about 1 million patients in the EU are diagnosed every year with VTE. The study, dubbed AMPLIFY, (Apixaban for the initial Management of PuLmonary embolIsm and deep vein thrombosis as First-line therapY), included 5,395 patients. The study tested 10 mg of Eliquis twice daily for seven days followed by 5 mg twice daily thereafter compared to current standard of care. PFE closed Friday at $28.01, down $0.17 or 0.60%, while BMY closed at $44.69, down $1.61 or 3.48%, both on the NYSE. Copyright RTT News/dpa-AFX © 2013 AFX News Nachrichten zu BRISTOL-MYERS SQUIBB COMPANY Zeit Aktuelle Nachrichten Di Bristol-Myers Squibb Shares Up 15.9% Since SmarTrend's Buy Recommendation --> Artikel lesen Mo Bristol-Myers Squibb Crosses Pivot Point Resistance at $52.76 --> Artikel lesen Mo Does Bristol-Myers Squibb Deserve Overweight Rating? --> Artikel lesen Mo Will Ariad Pharmaceuticals Lose to Novartis and Bristol-Myers Squibb? --> Artikel lesen Fr Bristol-Myers Squibb Shifts R&D Focus --> Artikel lesen Nachrichten zu PFIZER INC Zeit Aktuelle Nachrichten Mo Potential for Anti-NGF Agents Builds With Partnership Between Pfizer and Eli Lilly --> Artikel lesen So Pfizer And Merck Continue To Battle Declining Revenue --> Artikel lesen So Protalix results show Pfizer collaboration disappointment --> Artikel lesen Fr Watch for Pfizer to Potentially Pullback After Gaining 1.33% Yesterday --> Artikel lesen Fr PFIZER INC - 10-Q, Quaterly Report --> Artikel lesen Firmen im Artikel Unternehmen / Aktien Kurs % BRISTOL-MYERS SQUIBB COMPANY 39,098 +0,40 % PFIZER INC 23,403 +0,65 % Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von  und  mit der Push-Technologie von   Wie bewerten Sie die aktuell angezeigte Seite? sehr gut 1 2 3 4 5 6 schlecht Problem melden Google+ Seite Nutzungsbasierte Onlinewerbung Nachrichten •  Aktienkurse •  DAX •  Xetra-Orderbuch •  Watchlist Ad hoc-Mitteilungen •  Nachrichten Börsen •  Aktien-Empfehlungen Branchen •  Medien •  Nachrichten-Archiv Impressum | AGB | Disclaimer •  Presse •  Mediadaten RSS-News von FinanzNachrichten.de kostenlos für Ihren Browser und Ihre Homepage Aufklappen Schliessen
